Finally, shares of Aurinia Pharmaceuticals skyrocketed 79%. The biopharmaceutical company said that its voclosporin treatment for lupus nephritis produced encouraging results in a phase 3 trial, raising hopes that it might win approval from the U.S. Food and Drug Administration. In the trial, voclosporin met the primary endpoint of significant renal response rates after 52 weeks, as well as several secondary endpoints addressing renal response and time to achieve favorable reductions in urinary protein-to-creatinine ratios. With no unexpected safety issues, the drug has Aurinia optimistic about its future prospects, and shareholders are equally excited about voclosporin's potential.